PubRank

CART19 Cells Effects in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma (UHKT-CAR19-01)

Clinical Trial ID NCT05054257

PubWeight™ 0.00‹?›

🔗 Visit the ClinicalTrials.gov page for NCT05054257

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011 18.99
2 A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2003 8.59
3 B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 2011 8.26
4 Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 2014 8.21
5 A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res 2006 7.09
6 Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood 2008 7.01
7 Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther 2009 6.91
8 Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 2014 5.60
9 Chromosomal transposition of PiggyBac in mouse embryonic stem cells. Proc Natl Acad Sci U S A 2008 4.98
10 Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 1997 4.60
11 Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol Ther 2007 4.07
12 Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol 2014 3.94
13 Results of a double-blind, placebo-controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia. Circulation 2008 2.82
14 A hyperactive piggyBac transposase for mammalian applications. Proc Natl Acad Sci U S A 2011 2.68
15 PiggyBac transposon mutagenesis: a tool for cancer gene discovery in mice. Science 2010 2.31
16 Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med 2015 2.20
17 Presidential address. Transposable elements, epigenetics, and genome evolution. Science 2012 1.99
18 Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. Mol Ther 2013 1.89
19 CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J Clin Invest 2016 1.75
20 Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using Sleeping Beauty system and artificial antigen presenting cells. PLoS One 2013 1.32
21 Naked plasmid DNA encoding fibroblast growth factor type 1 for the treatment of end-stage unreconstructible lower extremity ischemia: preliminary results of a phase I trial. J Vasc Surg 2002 1.21
22 Evaluating risks of insertional mutagenesis by DNA transposons in gene therapy. Transl Res 2013 1.01
23 Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells. J Clin Invest 2016 0.96
24 Gene transfer vector biodistribution: pivotal safety studies in clinical gene therapy development. Gene Ther 2004 0.92
25 Mature T-cell lymphomagenesis induced by retroviral insertional activation of Janus kinase 1. Mol Ther 2013 0.82
26 Evaluating the potential for undesired genomic effects of the piggyBac transposon system in human cells. Nucleic Acids Res 2015 0.81
27 Clinical pharmacology of CAR-T cells: Linking cellular pharmacodynamics to pharmacokinetics and antitumor effects. Biochim Biophys Acta 2015 0.76
28 PiggyBac transposon vectors: the tools of the human gene encoding. Transl Lung Cancer Res 2016 0.76
29 Lenalidomide enhances antitumor functions of chimeric antigen receptor modified T cells. Oncoimmunology 2015 0.76
30 Kinetics and Biomarkers of Severe Cytokine Release Syndrome after CD19 Chimeric Antigen Receptor-modified T Cell Therapy. Blood 2017 0.75
31 Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment concepts. EMBO Mol Med 2017 0.75
32 Transposons: Moving Forward from Preclinical Studies to Clinical Trials. Hum Gene Ther 2017 0.75
33 Chimeric Antigen Receptors: A Cell and Gene Therapy Perspective. Mol Ther 2017 0.75
34 T lymphocytes are not immune. Mol Ther 2013 0.75
Next 100